Profile data is unavailable for this security.
About the company
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
- Revenue in AUD (TTM)1.62m
- Net income in AUD-36.43m
- Incorporated2003
- Employees8.00
- LocationZelira Therapeutics LtdLevel 3, 101 St Georges TerracePERTH 6000AustraliaAUS
- Phone+61 86558-0886
- Fax+61 86316-3337
- Websitehttps://zeliratx.com/home/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Holista Colltech Limited | 5.95m | -4.81m | 2.79m | 3.00 | -- | -- | -- | 0.4686 | -0.0172 | -0.0172 | 0.0213 | -0.0071 | 1.35 | 2.49 | 4.70 | -- | -111.49 | -42.59 | -347.69 | -63.58 | 56.66 | 56.37 | -82.68 | -39.27 | 0.2845 | -- | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
| Hydration Pharmaceuticals Co Ltd | 15.20m | -12.27m | 3.96m | -- | -- | -- | -- | 0.2608 | -0.0629 | -0.0629 | 0.0779 | -0.002 | 1.18 | 1.61 | 6.60 | -- | -94.86 | -79.98 | -143.75 | -111.57 | 53.70 | 48.73 | -80.69 | -99.53 | 1.37 | -21.48 | 1.10 | -- | 10.34 | 19.27 | 23.61 | -- | -- | -- |
| Bod Science Ltd | 3.32m | -7.95m | 4.26m | -- | -- | -- | -- | 1.28 | -0.0557 | -0.0557 | 0.0235 | -0.0046 | 0.7533 | 2.42 | 8.05 | -- | -180.40 | -94.62 | -465.66 | -145.77 | 69.23 | 47.08 | -239.47 | -129.48 | 0.8319 | -- | 3.71 | -- | -34.70 | 23.20 | -47.10 | -- | 8.23 | -- |
| Cambium Bio Ltd | -28.22k | -366.01k | 5.36m | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | -0.00009 | -0.0036 | -0.039 | -- | -- | -- | -50.58 | -49.44 | -- | -292.47 | -- | -- | -- | -118.34 | -- | -- | -- | -- | -- | -- | 60.86 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.62m | -36.43m | 5.45m | 8.00 | -- | -- | -- | 3.36 | -3.23 | -3.23 | 0.148 | -0.2063 | 0.0848 | 0.185 | 3.55 | -- | -193.14 | -27.71 | -243.04 | -28.81 | 82.28 | -- | -2,278.17 | -508.48 | 0.1488 | -22.80 | -- | -- | -80.95 | -0.3635 | 53.35 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 3.94m | 761.17k | 6.22m | -- | 7.96 | 1.63 | 7.48 | 1.58 | 0.0054 | 0.0054 | 0.0273 | 0.0264 | 1.02 | -- | 76.13 | -- | 19.64 | -55.72 | 23.29 | -60.89 | -- | -- | 19.34 | -301.54 | -- | 54.64 | 0.00 | -- | 7,292.97 | 179.97 | 89.76 | -- | -- | -- |
| Invex Therapeutics Ltd | 837.95k | -6.01m | 6.31m | -- | -- | 1.19 | -- | 7.53 | -0.08 | -0.08 | 0.0112 | 0.0705 | 0.0521 | -- | 2.79 | -- | -37.38 | -- | -40.06 | -- | -- | -- | -717.76 | -- | -- | -- | 0.00 | -- | 379.22 | -- | -96.04 | -- | -- | -- |
| Terragen Holdings Ltd | 2.60m | -2.53m | 6.64m | -- | -- | 0.9719 | -- | 2.55 | -0.0099 | -0.0099 | 0.0101 | 0.0185 | 0.3364 | 0.5758 | 11.93 | -- | -32.71 | -43.86 | -39.59 | -50.11 | 96.61 | 87.96 | -97.24 | -173.81 | 5.79 | -347.50 | 0.0587 | -- | 13.67 | 31.22 | 40.19 | -- | -12.30 | -- |
| Vectus Biosystems Ltd | 86.39k | -2.49m | 6.92m | -- | -- | 2.92 | -- | 80.07 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
| Epsilon Healthcare Ltd | 7.21m | -5.93m | 7.21m | -- | -- | 0.7868 | -- | 0.9994 | -0.0198 | -0.0198 | 0.0241 | 0.0305 | 0.3839 | 17.94 | 2.73 | -- | -31.54 | -35.68 | -46.30 | -41.11 | 37.99 | 26.88 | -82.17 | -197.56 | 0.5237 | -9.28 | 0.2329 | -- | 29.36 | 30.99 | -43.77 | -- | 8.14 | -- |
| Island Pharmaceuticals Ltd | 10.28k | -2.37m | 7.74m | -- | -- | 9.75 | -- | 752.74 | -0.026 | -0.026 | 0.0001 | 0.007 | 0.0038 | -- | 0.0318 | -- | -88.77 | -- | -134.02 | -- | -- | -- | -23,100.68 | -- | -- | -- | 0.4433 | -- | -- | -- | -8.58 | -- | -- | -- |
